Core Points - Wharton Technology Co., Ltd. has announced the receipt of the "Investment Project Filing Certificate" from the Nanjing Jiangbei New Area Administrative Approval Bureau for its membrane materials and membrane components capacity enhancement project (Phase I) [1] - The total investment for the project is 550 million yuan (approximately 55 million) [1] - The announcement indicates that this is merely a government filing and that the investment is subject to internal approvals and various risk factors, leading to significant uncertainty [1] Summary by Category Project Details - The project is named "Membrane Materials and Membrane Components Capacity Enhancement Project (Phase I)" [1] - The project will be located in the New Material Science and Technology Park in Nanjing, Jiangsu Province [1] - The total investment for the project is 55 million yuan [1] Regulatory and Approval Process - The announcement confirms that the project has received the necessary government filing but still requires internal approval processes [1] - The investment is not classified as a related party transaction or a major asset restructuring as per the regulations [1] Investor Communication - Wharton Technology will fulfill its information disclosure obligations based on the project's progress [1] - The company has reminded investors to be aware of investment risks associated with the project [1]

关于取得投资项目备案证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 沃顿科技股份有限公司（以下简称"公司"）近日收到南京江北 新区管理委员会行政审批局出具的《江苏省投资项目备案证》，主要 内容如下： 项目名称：膜用材料及膜组件能力提升项目（一期） 项目法人：沃顿科技股份有限公司 证券代码：000920 证券简称：沃顿科技 公告编号：2025-054 沃顿科技股份有限公司 本次公告事项仅为获得政府部门对上述项目的备案，项目投资事 项尚需履行内部审批等程序，且受到政策、市场、环境等多种风险因 素影响，存在较大不确定性，最终项目投资方案以公司最终审议通过 为准。本次项目投资事项不构成关联交易，不构成《上市公司重大资 产重组管理办法》规定的重大资产重组，公司将根据项目进展情况及 时履行相应的审批程序和信息披露义务，敬请广大投资者注意投资风 险。 特此公告。 沃顿科技股份有限公司董事会 2025 年 10 月 9 日 建设地点：江苏省南京市江北新区新材料科技园 项目总投资：55,000 万元 ...

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

证券日报网讯沃顿科技（000920）9月30日在互动平台回答投资者提问时表示，截至2025年9月19日，公 司股东数量为31925户。 ...

Performance Forecasts - Yinglian Co., Ltd. expects a net profit growth of 1531.13% to 1672.97% year-on-year for the first three quarters [1] - Dalian Heavy Industry anticipates a net profit growth of 19.91% to 28.52% year-on-year for the first three quarters [1] Project Investments - Wharton Technology plans to invest in the enhancement of membrane materials and membrane components [1] - Jiufeng Energy intends to invest in a coal-to-natural gas project in Xinjiang [1] Contract Awards - Qiaoyin Co., Ltd. is pre-awarded a contract worth approximately 512 million yuan for integrated sanitation operations in Laishui County, Baoding City, Hebei Province [1] - Dash Smart signed a contract for a smart hospital project worth 113 million yuan [1] Equity Acquisitions - Conch New Materials plans to acquire 51% equity in North China Plastics [1] - Suochen Technology intends to acquire 60% equity in Likong Technology [1] - Jingye Intelligent plans to acquire 51% equity in Hefei Shengwen for 108 million yuan [1] - Landi Group plans to acquire 20.1667% equity in Jujia Technology for 121 million yuan [1] Share Buybacks - Hanshuo Technology plans to repurchase shares worth between 150 million yuan and 300 million yuan [2] - Youke De intends to spend between 8 million yuan and 10 million yuan on share buybacks [2] H-Shares - Jinghe Integrated Circuit has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [2] - Lingyi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange [2] - Changchun High-tech has submitted an application for the issuance of H-shares [2] Shareholding Changes - Senba Sensor's actual controller plans to reduce holdings by no more than 1.09% [3] - Erkang Pharmaceutical's controlling shareholder intends to reduce holdings by no more than 2.04% [3] - Andeli's BVI Donghua plans to reduce holdings by no more than 1.00% [3] - Zhiyang Innovation's controlling shareholder and its concerted actioner plan to reduce a total of no more than 4.225 million shares [3] - Xizi Clean Energy's chairman plans to increase holdings by 30 million to 50 million yuan [3] Other Activities - Luoxin Pharmaceutical plans to raise no more than 842 million yuan for innovative drug research and development projects [3] - Huaxin Xinchang has received project designation notification from Jiangqi Group [3] - Jinpu Garden plans to raise no more than 129 million yuan through a private placement to Nanjing Lisen [3]

Market Performance - The three major A-share indices collectively rose on September 29, with the ChiNext Index increasing by 2.74% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 21,781.43 billion yuan, an increase of over 12 billion yuan compared to the previous trading day [1] - More than 3,500 stocks closed higher, with 68 stocks hitting the daily limit up [1] Sector Performance - The leading sectors included metals such as zinc, nickel, and lead, while sectors like pork and military equipment restructuring saw significant declines [2] Institutional Ratings - A total of 21 buy ratings were issued by institutions today, covering 20 stocks, with three stocks receiving target price forecasts [3] - Stocks with buy ratings from institutions averaged a rise of 2.34%, outperforming the Shanghai Composite Index [4] Stock Highlights - Notable stocks that rose today included Lingyi Zhi Manufacturing and New Australia Holdings, with significant gains [5] - The top gainers included Feilihua, Luzhou Laojiao, and Huhua Electric, with increases of 5.24%, 4.3%, and 3.18% respectively [5] Institutional Buying and Selling - In the Dragon and Tiger list, 12 stocks saw net buying from institutions, with Tianqi Materials and Chuling Information receiving over 100 million yuan in net purchases [6] - The top net buying amounts included Tianqi Materials at 1 billion yuan and Lingyi Zhi Manufacturing at 987.78 million yuan [6] - Among the stocks sold by institutions, New Light Optoelectronics faced the highest net selling at 144 million yuan [7] Northbound Capital - Northbound funds saw net buying in 11 stocks, with Lingyi Zhi Manufacturing and Tianqi Materials leading the way [7] - Three stocks experienced net selling from northbound funds, with Wanxiang Qianchao facing a net sell of 105 million yuan [8] Company Announcements - Jingye Intelligent plans to acquire a 51% stake in Hefei Shengwen Information Technology for 1.08 billion yuan, aiming to enhance its military industry strategy [9] - Walton Technology is in the proposal stage for a project to enhance membrane materials and components, subject to internal approvals and market conditions [9] - ST Mingjiahui has received a court ruling for restructuring, which may lead to delisting risks if the restructuring fails [10] - Huayou Cobalt's subsidiary signed a supply agreement with LG Energy Solution for 76,000 tons of ternary precursor products from 2026 to 2030 [11] - China CRRC announced several major contracts totaling approximately 543.4 billion yuan, representing 22% of its projected 2024 revenue [11] - ST Mubang's actual controller is under investigation by the China Securities Regulatory Commission for failing to disclose non-operating fund transactions [11]

值得注意的是，此次投资事项既不构成关联交易，也不构成《上市公司重大资产重组管理办法》规定的 重大资产重组。公司表示，将依据项目进展情况，及时履行相应的审批程序与信息披露义务，同时提醒 广大投资者注意投资风险。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 登录新浪财经APP 搜索【信披】查看更多考评等级 沃顿科技股份有限公司（证券代码：000920，证券简称：沃顿科技）于2025年9月30日发布关于拟投资 项目的提示性公告。公告显示，公司为积极把握膜行业发展的市场机遇，推动自身高质量发展，依据未 来发展战略及行业发展形势，计划投资建设膜用材料及膜组件能力提升项目。 目前，该项目尚处于方案论证阶段。项目投资事项不仅需履行内部 ...

Core Viewpoint - Wharton Technology (000920.SZ) is planning to invest in the enhancement of membrane materials and membrane component capabilities to seize market opportunities in the membrane industry and promote high-quality development [1] Group 1 - The project is currently in the proposal verification stage [1] - The investment plan is subject to internal approval and project filing procedures [1] - The project faces significant uncertainties due to various risk factors including policy, market, and environmental influences [1]

关于拟投资项目的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 沃顿科技股份有限公司（以下简称"公司"）为积极抓住膜行业发 展的市场机遇，促进公司高质量发展，公司根据未来发展战略及行业 发展形势，拟投资建设膜用材料及膜组件能力提升项目（以下简称"项 目"）。项目目前处于方案论证阶段，项目投资事项尚需履行内部审批、 项目备案等相关程序，且受到政策、市场、环境等多种风险因素影响， 存在较大不确定性，最终项目投资方案以公司最终审议通过为准。本 事项不构成关联交易，不构成《上市公司重大资产重组管理办法》规 定的重大资产重组，公司将根据项目进展情况及时履行相应的审批程 序和信息披露义务，敬请广大投资者注意投资风险。 证券代码：000920 证券简称：沃顿科技 公告编号：2025-053 沃顿科技股份有限公司 沃顿科技股份有限公司董事会 2025 年 9 月 30 日 特此公告。 ...

Core Viewpoint - The company aims to seize market opportunities in the membrane industry by investing in the enhancement of membrane material and component capabilities, currently in the project proposal stage [1] Group 1 - The project is focused on improving the company's capabilities in membrane materials and components [1] - The investment amount and specific plans for the project have not yet been determined [1] - The final investment plan will be subject to the company's approval [1]